Anaplastic Thyroid Cancer - Pipeline Review, H2 2016

  • ID: 3821710
  • Report
  • 73 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Genelux Corporation
  • Novartis AG
  • Pfizer Inc.
  • Plexxikon Inc.
  • Trophogen, Inc.
  • MORE
Anaplastic Thyroid Cancer - Pipeline Review, H2 2016

Summary

‘Anaplastic Thyroid Cancer - Pipeline Review, H2 2016’, provides an overview of the Anaplastic Thyroid Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anaplastic Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Thyroid Cancer and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anaplastic Thyroid Cancer
- The report reviews pipeline therapeutics for Anaplastic Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anaplastic Thyroid Cancer therapeutics and enlists all their major and minor projects
- The report assesses Anaplastic Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anaplastic Thyroid Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anaplastic Thyroid Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anaplastic Thyroid Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Genelux Corporation
  • Novartis AG
  • Pfizer Inc.
  • Plexxikon Inc.
  • Trophogen, Inc.
  • MORE
List of Figures

Introduction

Report Coverage

Anaplastic Thyroid Cancer Overview

Therapeutics Development

Pipeline Products for Anaplastic Thyroid Cancer - Overview

Pipeline Products for Anaplastic Thyroid Cancer - Comparative Analysis

Anaplastic Thyroid Cancer - Therapeutics under Development by Companies

Anaplastic Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes

Anaplastic Thyroid Cancer - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Anaplastic Thyroid Cancer - Products under Development by Companies

Anaplastic Thyroid Cancer - Products under Investigation by Universities/Institutes

Anaplastic Thyroid Cancer - Companies Involved in Therapeutics Development

Daiichi Sankyo Company, Limited

Genelux Corporation

Immune Pharmaceuticals Inc.

Millennium Pharmaceuticals Inc

Novartis AG

Pfizer Inc.

Plexxikon Inc.

Trophogen, Inc.

Anaplastic Thyroid Cancer - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ceritinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLM-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crizotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crolibulin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

efatutazone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GLONC-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GLV-1h153 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pexidartinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-8394 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Antagonize VEGF and PDGF for Anaplastic Thyroid Cancer and Wound Healing - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sapanisertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

utomilumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Anaplastic Thyroid Cancer - Dormant Projects

Anaplastic Thyroid Cancer - Product Development Milestones

Featured News & Press Releases

Apr 18, 2013: Combination Therapy Shows Promise Against Anaplastic Thyroid Cancer, Study Finds

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Anaplastic Thyroid Cancer, H2 2016

Number of Products under Development for Anaplastic Thyroid Cancer - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Anaplastic Thyroid Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2016

Anaplastic Thyroid Cancer - Pipeline by Genelux Corporation, H2 2016

Anaplastic Thyroid Cancer - Pipeline by Immune Pharmaceuticals Inc., H2 2016

Anaplastic Thyroid Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016

Anaplastic Thyroid Cancer - Pipeline by Novartis AG, H2 2016

Anaplastic Thyroid Cancer - Pipeline by Pfizer Inc., H2 2016

Anaplastic Thyroid Cancer - Pipeline by Plexxikon Inc., H2 2016

Anaplastic Thyroid Cancer - Pipeline by Trophogen, Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Anaplastic Thyroid Cancer - Dormant Projects, H2 2016 70List of Figures

Number of Products under Development for Anaplastic Thyroid Cancer, H2 2016

Number of Products under Development for Anaplastic Thyroid Cancer - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Daiichi Sankyo Company, Limited
Genelux Corporation
Immune Pharmaceuticals Inc.
Millennium Pharmaceuticals Inc
Novartis AG
Pfizer Inc.
Plexxikon Inc.
Trophogen, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll